In-Depth Research on Vascular Endothelial Growth Factor B - Pipeline Review, H2 2016

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted pipeline therapeutics.

The report provides comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Alteogen Inc. Clearside BioMedical, Inc. CSL Limited Eli Lilly and Company Formycon AG Regeneron Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###